Key result
Emerging pacing trial evidence shows unclear impact on real-world clinical practice.
Why the study?
It is unclear whether the emerging results of randomized clinical trials have affected the clinical practice of cardiac pacing.
The paper discusses the necessity of randomized clinical trials to evaluate small-to-moderate benefits of advanced pacing technologies and questions their impact on clinical practice.
Answers are grounded in this paper and cite their sources.
Advanced pacing technologies should not alter practice without RCTs; leaves open whether modest benefits justify adoption.
Randomized clinical trials are the gold standard for the evaluation of new therapies. However, in the early years of pacing, the observational benefits were so great and the lifesaving benefits to patients so readily obvious that randomized trials were not necessary to prove benefit. As the technology has matured, advances have become more evolutionary than revolutionary, and observational analyses are unable to provide convincing evidence of small-to-moderate benefits. Thus, randomized trials of sufficient sample size are necessary to reliably assess the small-to-moderate effects of advances such as dual-chamber pacing, rate modulation, and mode switching. It is only during the last decade, however, that the evidence base for pacing with regard to randomized trials has begun to emerge. It is unclear whether the emerging results of these clinical trials have affected the clinical practice of pacing.
No takes yet. Share an insight, caveat, or question.
Lamas et al. (2003) conducted a review in Cardiac pacing. Cardiac pacing was evaluated. The evidence base for cardiac pacing from randomized clinical trials has begun to emerge, but it remains unclear whether these results have affected clinical practice.
Synapse has enriched 10 related papers. Consider them for comparative context: